GLP recognition demonstrates that CNL meets internationally recognized standards for laboratory studies, ensuring the reliability, reproducibility, and integrity of the data generated, and is critical ...
Company remains on track to submit Investigational Device Exemption (“IDE”), and if approved, commence U.S. clinical trials in 2026 to support a De Novo FDA application THE WOODLANDS, TX, Sept. 29, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results